Welcome to our dedicated page for Concert Pharmaceuticals news (Ticker: CNCE), a resource for investors and traders seeking the latest updates and insights on Concert Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Concert Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Concert Pharmaceuticals's position in the market.
Concert Pharmaceuticals (NASDAQ: CNCE) plans to announce its first quarter 2022 financial results on May 5, 2022, before U.S. markets open. A conference call and webcast will be held at 8:30 a.m. ET to discuss the results and provide a business update. Interested participants can join by calling (855) 354-1855 for U.S./Canada and (484) 365-2865 for international callers. The live webcast can be accessed on the company's website and will be available for three months post-event.
Concert Pharmaceuticals reported its financial results for the year ended December 31, 2021, revealing a revenue increase to $32.6 million from $7.9 million in 2020. This rise was primarily due to a $32 million payment from Vertex Pharmaceuticals. Research and development expenses surged to $87.6 million from $61.6 million, reflecting ongoing trials for CTP-543, aimed at treating alopecia areata. The net loss for 2021 was $80.1 million, or $2.33 per share, slightly improved from the previous year's loss of $74.8 million. The company expects to file an NDA for CTP-543 in the first half of 2023.
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) will release its fourth quarter 2021 financial results on March 3, 2022, before U.S. markets open. A conference call and webcast will follow at 8:30 a.m. ET to discuss the results and provide a business update. Interested participants can join by calling (855) 354-1855 for the U.S. and Canada, or (484) 365-2865 internationally. A live and recorded version of the webcast will be available on the Company’s website for three months.
Concert Pharmaceuticals (NASDAQ: CNCE) has successfully completed patient enrollment in its THRIVE-AA2 Phase 3 trial aimed at assessing the efficacy and safety of CTP-543 for moderate to severe alopecia areata. This trial joins THRIVE-AA1, which concluded enrollment in October 2021, with topline data anticipated for both trials in mid-2022. CTP-543 has received Breakthrough Therapy and Fast Track designations from the FDA, highlighting its potential as a treatment option for this autoimmune condition affecting approximately 1.5 million Americans.
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced its participation in the H.C. Wainwright BIOCONNECT Virtual Conference from January 10-13, 2022. An on-demand presentation will begin at 7:00 a.m. ET on January 10, with a replay available for two weeks afterward. Concert is a clinical-stage biopharmaceutical company focused on developing novel small molecule drugs using its DCE Platform, aimed at improving pharmacokinetic properties. Their lead candidate targets alopecia areata, an autoimmune skin condition. For details, visit www.concertpharma.com.
Concert Pharmaceuticals (NASDAQ: CNCE) announced its participation in a virtual fireside chat at The Jefferies London Healthcare Conference. This on-demand chat will be available starting at 8:00 a.m. GMT on November 18, 2021. Investors can access the webcast through the Investors section of Concert's website. A replay will be available for two weeks post-presentation. Concert Pharmaceuticals focuses on developing small molecule drugs using its DCE Platform, with its lead candidate in late-stage development for treating alopecia areata.
Concert Pharmaceuticals (NASDAQ: CNCE) has fully enrolled its CTP-543 THRIVE-AA1 Phase 3 trial, targeting patients with moderate to severe alopecia areata, expecting topline data in Q2 2022. The THRIVE-AA2 trial continues with results anticipated in H2 2022. Financially, Q3 2021 reported revenue of $0.5 million, down from $1.5 million in Q3 2020. R&D expenses increased to $21.9 million, while net loss rose to $26.7 million, or $0.78 per share. Cash and equivalents totaled $103.7 million, supported by a recent $65 million capital raise, expected to fund operations into Q4 2022.
Concert Pharmaceuticals (NASDAQ: CNCE) has announced a financing deal with BVF Partners L.P. and RA Capital Management to raise
Concert Pharmaceuticals (NASDAQ: CNCE) will announce its third quarter 2021 financial results on November 9, 2021, prior to U.S. market opening. A conference call will follow at 8:30 a.m. ET, where the company will discuss its results and provide a business update. Interested participants can join by dialing (855) 354-1855 in the U.S. or (484) 365-2865 internationally. A live webcast will be available on the company’s website, with a replay accessible for three months.
Concert is focused on developing small molecule drugs through its DCE Platform, including a candidate for alopecia areata treatment.
Concert Pharmaceuticals (NASDAQ: CNCE) announced the completion of patient enrollment in the Phase 3 clinical trial THRIVE-AA1, assessing CTP-543, an oral JAK inhibitor for moderate to severe alopecia areata. This trial, which includes 708 participants aged 18 to 65, aims to evaluate hair regrowth after 24 weeks. Topline results are anticipated in Q2 2022. The company holds Breakthrough Therapy designation from the FDA for CTP-543, with a New Drug Application submission expected in early 2023 if results are positive.
